Evicita · Supplement evidence, graded and cited · Supplements · Lifestyle · Mechanisms · Lab tests · 中文

Boswellia extract (acetyl-11-keto-beta-boswellic acid, AKBA)

Boswellia Serrata Extract (AKBA / ApresFlex) · also known as Boswellic acids, AKBA, ApresFlex, 5-Loxin

In vitro, AKBA can inhibit 5-lipoxygenase (5-LOX). A human randomized trial showed that 5-Loxin can lower synovial fluid MMP-3, but plasma LTB4 did not fall after oral boswellia extract. Its anti-inflammatory mechanism and cartilage-repair effects in humans have not been confirmed.

Typical dose: Concentrated standardized AKBA extract, 100–250 mg/day, with a meal
Absorption and forms: Ordinary boswellia extracts contain less than 3% AKBA and are poorly absorbed. Proprietary extracts such as ApresFlex and 5-Loxin differ in composition, standardized content (some are standardized to 20–30% AKBA) and pharmacokinetics. They should not all be assumed to use the same lipid carrier or to give the same fold increase in absorption.

Clinical uses and human evidence

Osteoarthritis pain

BeneficialGrade B · Moderate evidence
Studies (2)
  1. Karlapudi 2023 · J Am Nutr Assoc · RCT · n=70 — Efficacy and Safety of Aflapin®, a Novel Boswellia Serrata Extract, in the Treatment of Osteoarthritis of the Knee: A Short-Term 30-Day Randomized, Double-Blind, Placebo-Controlled Clinical Study
  2. Kumar 2025 · J Am Nutr Assoc · RCT · n=80 — A Standardized Boswellia serrata Extract Improves Knee Joint Function and Cartilage Morphology in Human Volunteers with Mild to Moderate Osteoarthritis in a Randomized Placebo-Controlled Study

Inflammation markers (such as CRP)

Mixed resultsGrade B · Moderate evidence
Studies (1)
  1. Karlapudi 2023 · J Am Nutr Assoc · RCT · n=70 — Efficacy and Safety of Aflapin®, a Novel Boswellia Serrata Extract, in the Treatment of Osteoarthritis of the Knee: A Short-Term 30-Day Randomized, Double-Blind, Placebo-Controlled Clinical Study

Diarrhea (including antibiotic-associated diarrhea)

Mixed resultsGrade C · Preliminary evidence
Studies (1)
  1. Madisch 2007 · Int J Colorectal Dis · RCT · n=31 — Boswellia serrata extract for the treatment of collagenous colitis. A double-blind, randomized, placebo-controlled, multicenter trial

Mechanisms of action

Joint cartilage matrix glycan (GAGs/Aggrecan) repair and lubrication

★★★☆☆Mechanism evidence: grade ASecondary target

In one randomized controlled trial, 5-Loxin lowered synovial fluid MMP-3, which supports a regulatory effect on pathways linked to cartilage matrix breakdown. However, this result does not yet show that cartilage structure regenerates, and it cannot be attributed to AKBA alone.

References (1)
  1. Sengupta 2008 · RCT: synovial fluid MMP-3 was found to decrease, supporting regulation of pathways involved in cartilage matrix breakdown

Inhibition of NF-κB / AP-1, the master switches of pro-inflammatory transcription

★★☆☆☆Mechanism evidence: grade DSecondary target

Findings of direct inhibition of IκB kinase (IKK) and blocking of NF-κB entry into the nucleus come mainly from in-vitro experiments at micromolar concentrations, and from cell and animal models. It is unclear whether free AKBA reaches effective concentrations at usual doses, and inflammation outcomes in humans cannot show that this target is responsible.

References (1)
  1. 2009 · Boswellic acid mechanism study: the pharmacological relevance of several in-vitro enzyme targets is limited by protein binding and human exposure

Direct inhibition of cyclooxygenase and lipoxygenase (COX-2 / 5-LOX) activity

★☆☆☆☆Mechanism evidence: grade DPrimary target

In vitro, AKBA can inhibit 5-LOX, thereby reducing leukotriene synthesis. However, plasma protein binding and low human exposure limit extrapolation to routine oral use, and plasma LTB4 also did not fall after oral boswellia extract. The degree of 5-LOX inhibition in humans is uncertain, and it cannot be claimed that there is no effect on COX-1 or the gastric mucosa.

References (1)
  1. 2009 · Human whole-blood and volunteer study: AKBA’s 5-LOX inhibition was markedly weaker in systems containing albumin or whole blood, and plasma LTB4 did not fall after oral boswellia extract

Collagen triple-helix cross-linking and fibril synthesis

★☆☆☆☆Mechanism evidence: grade DSecondary target

The fall in synovial fluid MMP-3 suggests that pathways involved in cartilage matrix breakdown may be modulated, but this result does not prove increased collagen synthesis or cross-linking. There is no human evidence for the collagen renewal this mechanism refers to.

References (1)
  1. Sengupta 2008 · RCT: 5-Loxin 100 or 250 mg/day lowered synovial fluid MMP-3, but collagen synthesis was not measured directly

Safety and drug interactions

Use with caution if you are allergic to boswellia (frankincense) resin. Very mild acid reflux occasionally occurs; taking it with a meal avoids this.
Open in the interactive app ›